A to Z / Sexual health

PT-141

Also known as Bremelanotide, Vyleesi.

Best known for The approved libido medicine, also used outside prescription

Evidence★★★★☆

Safety dataWell characterised

Route injectable (subcutaneous) · nasal (investigational)

United StatesFDA approved

AustraliaNot named in the Poisons Standard

as at 16 September 2026

What it is

PT-141, bremelanotide, is a melanocortin receptor agonist approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

It is unusual in this book: a compound that completed phase-3 trials and reached approval, which is also available through research-chemical suppliers and used by a very different population for a different purpose.

It is chemically related to the melanotans, and shares some of their side effects.

What the full entry covers

The book carries the rest of this entry:

Where the research stands, with every claim cited
What people commonly ask, and what the research shows so far
Dosing in four labelled bands, described and not recommended
Side effects, serious risks, cautions and interactions
Questions to discuss with your doctor
How it compares with Kisspeptin-10, Melanotan II, Melanotan I, Gonadorelin

Related entries

Kisspeptin-10The upstream switch for reproductive hormones · Evidence ★★☆☆☆
Melanotan IIThe injectable tanning peptide · Evidence ★☆☆☆☆
Melanotan IThe melanotan that became an approved medicine · Evidence ★★★★☆
GonadorelinThe TRT adjunct that isn't hCG · Evidence ★★★★☆

A certificate of analysis tells you what is in a vial. The evidence rating above tells you whether the compound has been shown to work in humans. Neither answers the other's question. How to read a certificate of analysis.

This page describes what is known and not known about PT-141. It is not medical advice and not a recommendation to use it.